227 related articles for article (PubMed ID: 30283959)
1. Drug and chemical induced photosensitivity from a clinical perspective.
Ibbotson S
Photochem Photobiol Sci; 2018 Dec; 17(12):1885-1903. PubMed ID: 30283959
[TBL] [Abstract][Full Text] [Related]
2. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study.
Stern RS; Liebman EJ; Väkevä L
J Natl Cancer Inst; 1998 Sep; 90(17):1278-84. PubMed ID: 9731734
[TBL] [Abstract][Full Text] [Related]
3. [Pharmaceutical chemistry of drug-initiated photosensitivity].
Rácz Á; Tóth L
Acta Pharm Hung; 2015; 85(2):51-70. PubMed ID: 26390736
[TBL] [Abstract][Full Text] [Related]
4. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients.
Lim JL; Stern RS
J Invest Dermatol; 2005 Mar; 124(3):505-13. PubMed ID: 15737190
[TBL] [Abstract][Full Text] [Related]
5. Light protection of the skin after photodynamic therapy reduces inflammation: an unblinded randomized controlled study.
Petersen B; Wiegell SR; Wulf HC
Br J Dermatol; 2014 Jul; 171(1):175-8. PubMed ID: 24506809
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced photosensitivity.
Prescrire Int; 2009 Oct; 18(103):208-11. PubMed ID: 19882789
[TBL] [Abstract][Full Text] [Related]
7. The Science and (Lost) Art of Psoralen Plus UVA Phototherapy.
Richard EG
Dermatol Clin; 2020 Jan; 38(1):11-23. PubMed ID: 31753184
[TBL] [Abstract][Full Text] [Related]
8. PUVA improvements will come from molecular biology.
Gasparro FP
Photodermatol Photoimmunol Photomed; 2000 Apr; 16(2):83-4. PubMed ID: 10823319
[No Abstract] [Full Text] [Related]
9. Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients.
Katz KA; Marcil I; Stern RS
J Invest Dermatol; 2002 Jun; 118(6):1038-43. PubMed ID: 12060400
[TBL] [Abstract][Full Text] [Related]
10. Iatrogenic skin cancer: induction by psoralen/ultraviolet A and immunosuppression of organ transplant recipients.
McKenna KE
Photodermatol Photoimmunol Photomed; 2004 Dec; 20(6):289-96. PubMed ID: 15533236
[TBL] [Abstract][Full Text] [Related]
11. Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A-treated patients with psoriasis.
Seidl H; Kreimer-Erlacher H; Bäck B; Soyer HP; Höfler G; Kerl H; Wolf P
J Invest Dermatol; 2001 Aug; 117(2):365-70. PubMed ID: 11511317
[TBL] [Abstract][Full Text] [Related]
12. Psoralen photochemotherapy, clinical efficacy, and photomutagenicity: the role of molecular epidemiology in minimizing risks.
Gasparro FP; Liao B; Foley PJ; Wang XM; McNiff JM
Environ Mol Mutagen; 1998; 31(2):105-12. PubMed ID: 9544188
[TBL] [Abstract][Full Text] [Related]
13. Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy.
Bellnier DA; Greco WR; Nava H; Loewen GM; Oseroff AR; Dougherty TJ
Cancer Chemother Pharmacol; 2006 Jan; 57(1):40-5. PubMed ID: 16001178
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous phototoxicity due to psoralens.
Gange RW; Parrish JA
Natl Cancer Inst Monogr; 1984 Dec; 66():117-26. PubMed ID: 6531018
[TBL] [Abstract][Full Text] [Related]
15. High frequency of ultraviolet mutations at the INK4a-ARF locus in squamous cell carcinomas from psoralen-plus-ultraviolet-A-treated psoriasis patients.
Kreimer-Erlacher H; Seidl H; Bäck B; Cerroni L; Kerl H; Wolf P
J Invest Dermatol; 2003 Apr; 120(4):676-82. PubMed ID: 12648234
[TBL] [Abstract][Full Text] [Related]
16. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review.
Archier E; Devaux S; Castela E; Gallini A; Aubin F; Le Maître M; Aractingi S; Bachelez H; Cribier B; Joly P; Jullien D; Misery L; Paul C; Ortonne JP; Richard MA
J Eur Acad Dermatol Venereol; 2012 May; 26 Suppl 3():22-31. PubMed ID: 22512677
[TBL] [Abstract][Full Text] [Related]
17. Combination of Fospeg-IPDT and a natural antioxidant compound prevents photosensitivity in a murine prostate cancer tumour model.
Petri A; Alexandratou E; Kyriazi M; Rallis M; Roussis V; Yova D
Photodiagnosis Photodyn Ther; 2012 Jun; 9(2):100-8. PubMed ID: 22594979
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks.
Sivanesan SP; Gattu S; Hong J; Chavez-Frazier A; Bandow GD; Malick F; Kricorian G; Koo J
J Am Acad Dermatol; 2009 Nov; 61(5):793-8. PubMed ID: 19766350
[TBL] [Abstract][Full Text] [Related]
19. Psoralen photochemotherapy.
McClelland PB; Morgan P; Leach EE; Shelk J
Dermatol Nurs; 1997 Dec; 9(6):403-15; quiz 416-7. PubMed ID: 9460332
[TBL] [Abstract][Full Text] [Related]
20. Hydrochlorothiazide-induced photosensitivity in a psoriasis patient following exposure to narrow-band ultraviolet B excimer therapy.
Rosenthal A; Herrmann J
Photodermatol Photoimmunol Photomed; 2019 Sep; 35(5):369-371. PubMed ID: 31006143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
